Evaluating the risk of cardiovascular events associated with different immunosuppression treatments for glomerular diseases
Evaluating the risk of cardiovascular events associated with different immunosuppression treatments for glomerular diseases is a paper indexed in ScholarIQ from OpenAlex.
How many citations does Evaluating the risk of cardiovascular events associated with different immunosuppression treatments for glomerular diseases have?
Evaluating the risk of cardiovascular events associated with different immunosuppression treatments for glomerular diseases has 16 citations in the OpenAlex counts ScholarIQ stores.
When was Evaluating the risk of cardiovascular events associated with different immunosuppression treatments for glomerular diseases published?
Evaluating the risk of cardiovascular events associated with different immunosuppression treatments for glomerular diseases has 2024 year in the ScholarIQ index.
What is the open-access status of Evaluating the risk of cardiovascular events associated with different immunosuppression treatments for glomerular diseases?
Evaluating the risk of cardiovascular events associated with different immunosuppression treatments for glomerular diseases has hybrid oa status in the ScholarIQ index.
What is the DOI of Evaluating the risk of cardiovascular events associated with different immunosuppression treatments for glomerular diseases?
The DOI for Evaluating the risk of cardiovascular events associated with different immunosuppression treatments for glomerular diseases is on the source record.
What is the PMID of Evaluating the risk of cardiovascular events associated with different immunosuppression treatments for glomerular diseases?
The PMID for Evaluating the risk of cardiovascular events associated with different immunosuppression treatments for glomerular diseases is on the source record.
What is the OpenAlex record for Evaluating the risk of cardiovascular events associated with different immunosuppression treatments for glomerular diseases?
The OpenAlex for Evaluating the risk of cardiovascular events associated with different immunosuppression treatments for glomerular diseases is on the source record.